Current medications such as corticosteroids remain ineffective at targeting this axis of COPD pathogenesis,24 and clinical trials using biologics against both IL‐1β and IL‐8 have lacked efficacy or failed to achieve safety outcomes.25, 26. Here, IL1B is linked to chronic obstructive pulmonary disease.